Margaret A. Horn, an insider of Revolution Medicines Inc (RVMD), sold 141,053 shares of the company's stock at a price of $76.82 per share, resulting in a total transaction value of $10.84 million on December 15, 2025. Following this transaction, Horn retains 141,053 shares of the company.
Revolution Medicines, a clinical-stage precision oncology firm headquartered in Redwood City, California, focuses on developing novel targeted therapies. The company, which employs 700 full-time staff, went public on February 13, 2020. Its research pipeline includes RAS(ON) inhibitors and RAS companion inhibitors, aimed at targeting specific RAS variants and associated pathways. Notable candidates in development include daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805).
The sale by Horn underscores the complexity of insider trading, which can stem from various factors such as diversification or personal financial needs. While significant insider selling may draw investor attention, it is essential to consider such transactions within a broader context. Insider trades must be reported to the SEC, providing transparency into the actions of company executives and board members. However, isolated transactions should not solely inform investment decisions; examining patterns of insider activity across multiple individuals and timeframes offers a more comprehensive perspective.
As of December 18, 2025, Revolution Medicines has a market capitalization of $14.8 billion, with a trailing twelve months (TTM) earnings per share (EPS) of -2.73. The company is set to release its next earnings report on May 5, 2026, with an EPS estimate of -1.70, followed by another report on August 4, 2026, where the EPS estimate stands at -1.76.